GL1X · GenesisL1 explorer

MolNFT v2 · #217917 · protein

8QJR: BRG1 bromodomain in complex with VBC via compound 17

8QJR · Elongin-B: “BRG1 bromodomain in complex with VBC via compound 17”. X-ray diffraction at 3.17, 3 ligands (VLH, PO4, CL), 7 pockets (best druggability 0.57). MolNFT v2 #217917 on GenesisL1: 3D structure, binding sites and pockets in…

3D structure of 8QJR: BRG1 bromodomain in complex with VBC via compound 17 (MolNFT v2 / PDB Bank)
3D structure of 8QJR: BRG1 bromodomain in complex with VBC via compound 17 (MolNFT v2 / PDB Bank)
PDB
8QJR
Type
protein
Length
898 residues
Chains
8
Method
x-ray diffraction
Authors
Kerry, P.S., Hole, A.J., Perez-Dorado, J.I.
Deposited
09/13/23
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
3.17
Source
Homo sapiens
Molecule
Elongin-B; Elongin-C; von Hippel-Lindau disease tumor suppressor; Transcription activator…
EC
3.6.4.-
UniProt
Q15370, Q15369, P40337, P51532
Ligands
VLH, PO4, CL
Pockets
7 · best druggability 0.57

Structure

x-ray diffraction · resolution 3.17 · 7 distinct chains · 41% helix, 20% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, DElongin-Bprotein10315% helix, 35% strandQ15370
BElongin-Cprotein8747% helix, 15% strandQ15369
Cvon Hippel-Lindau disease tumor suppressorprotein15330% helix, 29% strandP40337
EElongin-Cprotein8747% helix, 15% strandQ15369
Fvon Hippel-Lindau disease tumor suppressorprotein15430% helix, 29% strandP40337
GTranscription activator BRG1 (EC 3.6.4.-)protein11065% helix, 2% strandP51532
HTranscription activator BRG1 (EC 3.6.4.-)protein10163% helix, 2% strandP51532

Ligands and binding sites

  • VLH · (2S,4R)-1-[(2R)-2-[3-[2-[4-[3-[4-[(1R,5S)-3-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]pyridin-2-yl]oxycyclobutyl]oxypiperidin-1-yl]ethoxy]-1,2-oxazol-5-yl]-3-methyl-butanoyl]-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]-4-oxidanyl-pyrrolidine-2-carboxamide · ligand · 2 copies · chains C, G, F, H
  • PO4 · Phosphate ion · ion · 7 copies · chains B, C, F, G
  • CL · Chloride ion · ion · chains D, E
  • GOL · Glycerol · additive · chains C, F

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11520.570.8232GOL
21520.560.8233empty
32640.490.7445empty
4620.480.8415empty
5660.460.8315empty

Interfaces

9 interfaces between chains.

  • A–B · 1195 Ų buried · 16 hydrogen bonds · protein-protein
  • D–E · 1153 Ų buried · 16 hydrogen bonds · protein-protein
  • B–C · 1118 Ų buried · 14 hydrogen bonds · protein-protein
  • C–F · 1097 Ų buried · 9 hydrogen bonds · protein-protein
  • E–F · 1096 Ų buried · 15 hydrogen bonds · protein-protein

Compared structures

  • Q15370 · AlphaFold monomer V2.0 prediction for elongin-B (Q15370) · a predicted model of the same protein · chain D against A, TM-score 0.99
  • P51532 · AlphaFold monomer V2.0 prediction for transcription activator BRG1 (P51532) · a predicted model of the same protein · chain H against A, TM-score 0.99
  • Q15369 · AlphaFold monomer V2.0 prediction for elongin-C (Q15369) · a predicted model of the same protein · chain B against A, TM-score 0.98
  • P40337 · AlphaFold monomer V2.0 prediction for von hippel-lindau disease tumor suppressor (P40337) · a predicted model of the same protein · chain F against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.